| Turkish Journal of Cancer |
| 2008, Volume 38, Number 3, Page(s) 123-134 |
|
[ Summary ]
[ Full Text ]
[ PDF ]
|
| The role of angiogenesis assessment in the prognosis of breast carcinoma and in the evaluation of the therapeutic effect of “shark care” drug as an angiogenesis inhibitor |
| NADIA ABD EL-MONEIM1, SAMIA ABD EL-MONEIM EBID2, AMANI KAZEM3, AHMED SAAD4, SAWSAN MOUSA5, EMAN EL-ABD5, TAHA HEWALA5 |
1Medical Research Institute, Departments of Clinical Oncology, Alexandria-Egypt 2Medical Research Institute, Departments of Applied Medical Chemistry, Alexandria-Egypt 3Medical Research Institute, Departments of Pathology, Alexandria-Egypt 4Medical Research Institute, Departments of Surgery, Alexandria-Egypt 5Medical Research Institute, Departments of Radiation Sciences, Alexandria-Egypt |
There is still uncertainty about angiogenesis as a prognostic
factor in breast cancer. The aim of this study was to evaluate
the prognostic value of microvascular density (MVD) in
breast carcinoma and soluble vascular cell adhesion molecule-
1 (sVCAM-1), leptin, estradiol and total testosterone
as angiogenic markers. Efficacy of shark care drug was
assessed by patient’s overall survival. In this study there
were 30 premenopausal breast cancer patients (group II)
and 15 controls (group I). Group II was subgrouped into
15 patients receiving chemotherapy alone (IIA) and 15 patients
receiving chemotherapy + shark care drug (IIB). After
modified radical mastectomy, microvessels were counted
by staining tissues for factor VIII. For surrogate markers,
enzyme-linked immunosorbant assay or radioimmunoassay
kits were used. A high MVD was found only in areas
of carcinoma. MVD and sVCAM-1 correlated significantly
with each other and with lymph node involvement. After the
follow up, all subgroup IIB patients were alive compared
to 66.6% of subgroup IIA patients (p=0.02). A high MVD
may be a poor prognostic marker of breast carcinoma and
a target for antiangiogenic therapy. sVCAM-1 is useful for
diagnosis and for monitoring response to therapy. Chemotherapy
+ shark care drug seem to ameliorate the outcome
of these patients. [Turk J Cancer 2008;38(3):123-134]
|
|
[ Summary ]
[ Full Text ]
[ PDF ]
|
Turkish Journal of Cancer web sitesi Novartis Onkoloji'nin karşılıksız eğitim katkılarıyla hazırlanmıştır.
|